Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Humacyte (HUMA) Gross Profit (2025)

Humacyte has reported Gross Profit over the past 1 years, most recently at -$8.6 million for Q4 2025.

  • Quarterly results put Gross Profit at -$8.6 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was -$7.7 million (changed N/A YoY), and the annual figure for FY2025 was -$7.7 million, changed.
  • Gross Profit for Q4 2025 was -$8.6 million at Humacyte, down from $493000.0 in the prior quarter.
  • Over the last five years, Gross Profit for HUMA hit a ceiling of $493000.0 in Q3 2025 and a floor of -$8.6 million in Q4 2025.